Lipocine Inc. (LPCN)
| Market Cap | 128.90M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.96M |
| Shares Out | 55.69M |
| EPS (ttm) | -0.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $1.46 |
| Previous Close | $1.42 |
| Change ($) | 0.04 |
| Change (%) | 2.82% |
| Day's Open | 1.40 |
| Day's Range | 1.35 - 1.47 |
| Day's Volume | 1,332,970 |
| 52-Week Range | 0.49 - 2.42 |
Amid risk-on sentiment, penny stocks are surging higher today as investors seek to grab the higher upside these small-cap stocks provide. The post Top Penny Stocks News Today: TNXP, ONTX, AREC, LPCN and...
SALT LAKE CITY, March 11, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company wil...
SALT LAKE CITY, March 11, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results fo...
SALT LAKE CITY, Jan. 28, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of an unde...
Lipocine Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications
SALT LAKE CITY, Jan. 14, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Patent Trial...
SALT LAKE CITY, Dec. 30, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it is enrolling ...
SALT LAKE CITY, Dec. 29, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that Judge William C....
Lipocine: Imminent Catalysts In NASH And Oral Testosterone Replacement Therapy Make For A Strong Buy
LPCN's long road to market for its oral testosterone pill has been bumpy; however, the FDA just gave TLANDO tentative approval.
SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and...
SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that an independent co...
SALT LAKE CITY, Dec. 4, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and...
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and o...
Lipocine is about to report data from its clinical study on whether TLANDO can restore testosterone levels in hypogonadal men without the dose titration requirement on November 9, 2020. Low baseline tes...
SALT LAKE CITY, Nov. 6, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and...
SALT LAKE CITY, Aug. 28, 2020 /PRNewswire/ -- Lipocine Inc.
SALT LAKE CITY, Aug. 6, 2020 /PRNewswire/ -- Lipocine Inc.
SALT LAKE CITY, Aug. 3, 2020 /PRNewswire/ -- Lipocine Inc.
SALT LAKE CITY, July 13, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has received ...
SALT LAKE CITY, May 15, 2020 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data for...
Lipocine Inc. (NASDAQ: LPCN) shares absolutely plummeted on Monday after the firm announced that it received a Complete Response Letter (CRL) from the U.S.
Lipocine Inc (NASDAQ: LPCN) shares are tumbling to record lows after an adverse FDA verdict on its lead drug Tlando, previously known as LPCN 1021.
Shares of Lipocine Inc. LPCN, -2.50% plummeted 67% toward a record low, and to pace all premarket losers, after the biopharmaceutical company said the Food and Drug Administration indicated that its New...
Lipocine Inc is seeing some momentum Tuesday morning after the company reported results of a study evaluating its non-alcoholic steatohepatitis (NASH) candidate.
About LPCN
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailabili... [Read more...]
| Industry Biotechnology | |
| CEO Mahesh Patel | Employees 11 |
| Stock Exchange NASDAQ | Ticker Symbol LPCN |
Analyst Forecasts
According to 2 analysts, the average rating for Lipocine stock is "Buy." The 12-month stock price forecast is 5.33, which is an increase of 265.07% from the latest price.